Health
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE – PharmiWeb.com
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE…
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
- This is the first authorisation to be issued by the MHRA under Project Orbis.1
- AstraZeneca, NHS England and NICE have reached an agreement to enable early access to osimertinib for patients with this type of cancer, while NICE undertakes its appraisal.
- Patients with early-stage lung cancer are treated…
Continue Reading
-
Noosa News18 hours agoGippsland vegetable farm accused of underpaying migrant workers
-
General19 hours agoFour escape injury after jumping from three-storey unit on fire in Newcastle
-
General17 hours agoIncreased police powers begin at Adelaide Oval Ashes Test following Bondi attacks
-
General24 hours agoDe-escalation skills, not guards, needed in Tasmanian hospitals, nurses’ union says